Drug Trial Radar · NCT02398773
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
99
Planned (sponsor's estimate)
Start
May 4, 2016
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Mar 26, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body. FES is a radioactive form of the hormone estrogen and may "light up" where cancer is in the body. Diagnostic procedures using FES, such as FES PET/CT, may help measure the FES and help doctors predict how well the cancer will respond to treatment.
Conditions
- HER2/Neu Negative
- Progesterone Receptor Negative
- Progesterone Receptor Positive
- Stage IV Breast Cancer AJCC v6 and v7
Interventions
Computed TomographyProcedure
Undergo PET/CT
F-18 16 Alpha-FluoroestradiolDrug
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
Positron Emission TomographyProcedure
Undergo PET/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Negative predictive value of 18F FES uptake for response (CB), defined as the proportion of patients with a negative FES test result who have progressive diseaseTime frame: At 6 months
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
City of Hope Comprehensive Cancer Center
Duarte, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana
Springmill Medical Center
Indianapolis, Indiana
Mayo Clinic in Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Mount Sinai Hospital
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Fox Chase Cancer Center - East Norriton Hospital Outpatient Center
East Norriton, Pennsylvania
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah
University of Washington Medical Center - Montlake
Seattle, Washington
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin
ProHealth D N Greenwald Center
Mukwonago, Wisconsin
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin
ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin
UW Cancer Center at ProHealth Care
Waukesha, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.